News
4h
Zacks Investment Research on MSNExelixis Gains 15.6% YTD: How Should You Play the Stock?
Exelixis’ EXEL year-to-date performance has been good. Shares of the biotech company have gained 15.6% compared with the ...
Today’s Stock of the Day list features three high-potential picks: Shilpa Medicare, Pfizer, and Vishal Mega Mart. Shilpa ...
Avant Technologies Inc. is an emerging technology company developing solutions in healthcare using artificial intelligence and biotechnologies. With a focus on pushing the boundaries of what is ...
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive ...
How Do Unusual Items Influence Profit? For anyone who wants to understand Pfizer's profit beyond the statutory numbers, it's ...
The gush of second quarter earnings reports is beginning to slow to a trickle, and with most of the reports in, the results ...
The gush of second quarter earnings reports is beginning to slow to a trickle, and with most of the reports in, the results have been mostly positive.
The recent portfolio rebalance increased FDL's risk and volatility, with 55% concentration in its top 10 holdings. Read why I ...
CureVac ( (CVAC)) has provided an announcement. On August 7, 2025, CureVac announced the resolution of U.S. patent litigation with Pfizer/BioNTech concerning mRNA-based COVID-19 vaccines. As part of ...
StockStory.org on MSN3d
Reflecting On Branded Pharmaceuticals Stocks’ Q2 Earnings: Royalty Pharma (NASDAQ:RPRX)
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...
Earnings season slows this week, with investors waiting on NVIDIA’s earnings on August 27. Retail sales and inflation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results